Acta Neuropathologica Communications · 2024 · 20 citations · 55 references
MedicineNeurologyNeuroscienceDementiaNeurodegenerationNeuropathologyAlzheimer DiseaseCerebrovascular DiseaseCognitive ImpairmentNeuroimaging In DementiaRetinal ImagingRetinal Vascular DiseaseAlzheimer Disease DementiaAlzheimer Disease Vascular PathologyAmyloid PlaquesCognitive Impairment AssociationsNeurocognitive DeclineNeurocognitive ImpairmentQuantitative NeuroimagingVascular Amyloid Deposition
The relationship between amyloidosis and vasculature in cognitive impairment and Alzheimer's disease (AD) pathogenesis is increasingly acknowledged. We conducted a quantitative and topographic assessment of retinal perivascular amyloid plaque (AP) distribution in individuals with both normal and impaired cognition. Using a retrospective dataset of scanning laser ophthalmoscopy fluorescence images from twenty-eight subjects with varying cognitive states, we developed a novel image processing method to examine retinal peri-arteriolar and peri-venular curcumin-positive AP burden. We further correlated retinal perivascular amyloidosis with neuroimaging measures and neurocognitive scores. Our study unveiled that peri-arteriolar AP counts surpassed peri-venular counts throughout the entire cohort (P < 0.0001), irrespective of the primary, secondary, or tertiary vascular branch location, with a notable increase among cognitively impaired individuals. Moreover, secondary branch peri-venular AP count was elevated in the cognitively impaired (P < 0.01). Significantly, peri-venular AP count, particularly in secondary and tertiary venules, exhibited a strong correlation with clinical dementia rating, Montreal cognitive assessment score, hippocampal volume, and white matter hyperintensity count. In conclusion, our exploratory analysis detected greater peri-arteriolar versus peri-venular amyloidosis and a marked elevation of amyloid deposition in secondary branch peri-venular regions among cognitively impaired subjects. These findings underscore the potential feasibility of retinal perivascular amyloid imaging in predicting cognitive decline and AD progression. Larger longitudinal studies encompassing diverse populations and AD-biomarker confirmation are warranted to delineate the temporal-spatial dynamics of retinal perivascular amyloid deposition in cognitive impairment and the AD continuum.
55
The Clinical Dementia Rating (CDR)
John C. Morris · Neurology · 1993 · 10K citations
Medicine, Neurology, Psychiatry +12
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text
Medicine, Neurology, Neuroscience +17
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Daniel A. Nation, Melanie D. Sweeney, Axel Montagne et al. · Nature Medicine · 2019 · 1.7K citations